GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aptabio Therapeutics Inc (XKRX:293780) » Definitions » Inventories, Finished Goods

Aptabio Therapeutics (XKRX:293780) Inventories, Finished Goods : ₩225 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Aptabio Therapeutics Inventories, Finished Goods?

Aptabio Therapeutics's quarterly finished goods increased from Jun. 2024 (₩0 Mil) to Sep. 2024 (₩30 Mil) and increased from Sep. 2024 (₩30 Mil) to Dec. 2024 (₩225 Mil).

Aptabio Therapeutics's annual finished goods stayed the same from Dec. 2022 (₩0 Mil) to Dec. 2023 (₩0 Mil) but then increased from Dec. 2023 (₩0 Mil) to Dec. 2024 (₩225 Mil).


Aptabio Therapeutics Inventories, Finished Goods Historical Data

The historical data trend for Aptabio Therapeutics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptabio Therapeutics Inventories, Finished Goods Chart

Aptabio Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Finished Goods
Get a 7-Day Free Trial - - - - 224.87

Aptabio Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 32.87 - 29.98 224.87

Aptabio Therapeutics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


Aptabio Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
13, Heungdeok 1-ro, Giheung-gu, Tower 504, Gyeonggi-do, Yongin-Si, KOR, 16954
Aptabio Therapeutics Inc is a South Korean pharmaceutical company involved in discovery and development of selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The product portfolio of the company include Lipofector-Q, Plusfector, Lipofector-EXT, Lipofector-2000, Lipofector-EZ and Lipofector-pMAX.

Aptabio Therapeutics Headlines

No Headlines